173838-67-0

Basic information

• Product Name: 2-[4-[4-(3-Pyridinyl)-1H-imidazol-1-yl]butyl]-1H-isoindole-1,3(2H)-dione
• Synonyms: 2-(4-(4-(PYRIDIN-3-YL)-1H-IMIDAZOL-1-YL)BUTYL)ISOINDOLINE-1,3-DIONE;4-(3-Pyridyl)-1H-imidazol-1-butanamide, phtalimide;4-(3-Pyridyl)-1H-imidazol-1-butanamide;2-[4-[4-(3-PYRIDINYL)-1H-IMIDAZOL-1-YL]BUTYL]-1H-ISOINDOLE-1,3(2H)-DIONE
• CAS NO: 173838-67-0
• Molecular Formula: C20H18N4O2
• Molecular Weight: 346.38
• Product Categories: Amines;Aromatics;Heterocycles
• Mol File: 173838-67-0.mol

Chemical Properties

• Boiling Point: 606.9 °C at 760 mmHg
• Flash Point: 320.8 °C
• Appearance: /
• Density: 1.30
• Refractive Index: 1.677
• Solubility: Dichloromethane
• PKA: 3.98±0.61(Predicted)
• CAS DataBase Reference: 2-[4-[4-(3-Pyridinyl)-1H-imidazol-1-yl]butyl]-1H-isoindole-1,3(2H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[4-[4-(3-Pyridinyl)-1H-imidazol-1-yl]butyl]-1H-isoindole-1,3(2H)-dione(173838-67-0)
• EPA Substance Registry System: 2-[4-[4-(3-Pyridinyl)-1H-imidazol-1-yl]butyl]-1H-isoindole-1,3(2H)-dione(173838-67-0)

Safety Data

• Hazardous Substances Data: 173838-67-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-[4-[4-(3-Pyridinyl)-1H-imidazol-1-yl]butyl]-1H-isoindole-1,3(2H)-dione is used as an intermediate compound in the preparation of erythromicins. Erythromicins are a class of macrolide antibiotics that are effective against a wide range of bacterial infections. The compound plays a crucial role in the synthesis process, contributing to the development of these life-saving drugs.
Chemical Properties:
The compound is an off-white solid, which indicates its stability and suitability for use in various chemical reactions and applications. Its unique chemical structure, featuring the imidazol-1-yl and pyridinyl groups, endows it with specific properties that make it valuable in the pharmaceutical industry.

InChI:InChI=1/C20H18N4O2/c25-19-16-7-1-2-8-17(16)20(26)24(19)11-4-3-10-23-13-18(22-14-23)15-6-5-9-21-12-15/h1-2,5-9,12-14H,3-4,10-11H2

Upstream product

• 5394-18-3 2-(4-bromobutyl)isoindoline-1,3-dione 
• 51746-85-1 3-(1H-imidazol-4-yl)pyridine 
• 350-03-8 methyl-3-pyridylketone 
• 5973-83-1 1-(pyridin-3-yl)ethan-1-one oxime 
• 74209-51-1 1-pyridin-3-yl-ethanone oxime O-tosylate 
• 51941-15-2 3-(α-aminoacetyl)pyridine 
• 93103-29-8 4-Pyridin-3-yl-1H-imidazole-2-thiol 

Downstream Products

• 191114-48-4 telithromycin 

Relevant articles and documents

Synthesis and Antibacterial Activity of Novel 4″-O-desosaminyl clarithromycin derivatives with 11, 12-arylalkyl side chains

A series of novel 4″-O-desosaminyl clarithromycin derivatives with 11, 12-arylalkyl side chains was synthesized by coupling 6-deoxy-desosamine donors (18, 19) with 4″-OH of compounds 5a–c. The activities of the target compounds were tested against a series of macrolide-sensitive and macrolide-resistant pathogens. Some of them showed activities against macrolide sensitive and resistant pathogens, and compounds 21d and 21e displayed significant improvement of activities against resistant pathogens.

Method of treating tuberculosis

Macrolide and ketolides, and compositions containing the same, useful in the treatment of tuberculosis are disclosed. Methods of treating tuberculosis using the macrolides and ketolides, and compositions containing the same, also are disclosed.

Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens

In the search for new ketolides with improved activities against erythromycin-resistant S. pneumoniae and H. influenzae we synthesized a new 11,12 carbamate ketolide substituted by an imidazo-pyridyl side chain: HMR 3647. This compound demonstrated a potent activity against erythromycin susceptible and resistant pathogens, including penicillin G/erythromycin A-resistant S. pneumoniae and H. influenzae. In vivo, HMR 3647 displayed good pharmacokinetic parameters (Cmax = 2.9 μg/ml, bioavailability = 49%, AUC0-8 = 17.2 μg.h/l, t( 1/2 )= lh) and was shown to have a high therapeutic efficacy in mice infected by various respiratory pathogens, including multi-resistant S. pneumoniae and Gram negative bacteria such as H. influenzae. HMR 3647 appears to be a very promising agent for the treatment of respiratory infections and is currently in clinical trials.